Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.
Nao MatsuyamaShinobu ShimizuKazuto UedaToshihiko SuzukiSakiko SuzukiRyosuke MiuraAkemi KatayamaMasahiko AndoMasaaki MizunoAkihiro HirakawaMasahiro HayakawaYoshiaki SatoPublished in: BMJ open (2022)
NCT04261335, jRCT2043190112.